Skip to contentD
Dare Bioscience, Inc.
D
DAREDare Bioscience, Inc. Q2 2024 · 10-Q
Revenue$22.44K$22.44K— vs Q2 2023 Net Income$12.91M$12.91MN/M vs Q2 2023 EPS Diluted$1.52$1.52N/M vs Q2 2023 Operating Income-$7,359,466N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Dare Bioscience, Inc. · CIK 1401914 · Engraved from SEC EDGAR
derived
Free Cash Flowderived$12,619,459N/M Margins · derivedOperating margin-32799.1%
Net margin57539.2%
ended Jun 30, 2024 · filed Aug 12, 2024 · 43 d after period end